Af­ter FDA hold and tri­al fail­ure, Ipsen writes down its big ac­qui­si­tion — but they're not giv­ing up

Near­ly a year ago, at the same time Roche shelled out $4.3 bil­lion on Spark Ther­a­peu­tics, Paris-based Ipsen bought its own bil­lion-dol­lar ac­qui­si­tion: Clemen­tia …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.